NO960811L - Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler - Google Patents

Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler

Info

Publication number
NO960811L
NO960811L NO960811A NO960811A NO960811L NO 960811 L NO960811 L NO 960811L NO 960811 A NO960811 A NO 960811A NO 960811 A NO960811 A NO 960811A NO 960811 L NO960811 L NO 960811L
Authority
NO
Norway
Prior art keywords
carbocyclic
compounds
suppressants
immune response
carboxylic acids
Prior art date
Application number
NO960811A
Other languages
English (en)
Norwegian (no)
Other versions
NO960811D0 (no
Inventor
Ronald Louis Magolda
William John Pitts
Irina Cipora Jacobson
Carl Henry Behrens
Michael James Orwat
Douglas Guy Batt
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO960811D0 publication Critical patent/NO960811D0/no
Publication of NO960811L publication Critical patent/NO960811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO960811A 1993-08-31 1996-02-28 Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler NO960811L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/114,712 US5428040A (en) 1993-08-31 1993-08-31 Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
PCT/US1994/009463 WO1995006640A1 (en) 1993-08-31 1994-08-26 Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents

Publications (2)

Publication Number Publication Date
NO960811D0 NO960811D0 (no) 1996-02-28
NO960811L true NO960811L (no) 1996-04-29

Family

ID=22356972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960811A NO960811L (no) 1993-08-31 1996-02-28 Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler

Country Status (19)

Country Link
US (4) US5428040A (cs)
EP (1) EP0716652A1 (cs)
JP (1) JPH09501442A (cs)
KR (1) KR960704851A (cs)
AU (1) AU690140B2 (cs)
CA (1) CA2170349A1 (cs)
CZ (1) CZ51696A3 (cs)
FI (1) FI960933A0 (cs)
HR (1) HRP940484A2 (cs)
HU (1) HUT74585A (cs)
IL (1) IL110821A (cs)
NO (1) NO960811L (cs)
NZ (1) NZ273156A (cs)
PL (1) PL313981A1 (cs)
RU (1) RU2133740C1 (cs)
SK (1) SK27096A3 (cs)
TW (1) TW342390B (cs)
WO (1) WO1995006640A1 (cs)
ZA (1) ZA946658B (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
DE69430752T2 (de) * 1993-09-28 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Tetracyclische verbindungen
US5681958A (en) * 1995-06-07 1997-10-28 Shaman Pharmaceuticals, Inc. Cryptolepine analogs with hypoglycemic activity
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
BR9711296A (pt) * 1996-09-23 1999-08-17 Univ Rutgers Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
GB9825632D0 (en) * 1998-11-23 1999-01-13 Novartis Ag Organic compounds
US7323471B1 (en) 1999-08-13 2008-01-29 Dor Biopharma, Inc. Topical azathioprine for the treatment of oral autoimmune diseases
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
BR0213100A (pt) * 2001-10-05 2004-11-30 Combinatorx Inc Combinações para o tratamento de distúrbios imuniinflamatórios
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
CA2467279A1 (en) * 2001-11-14 2003-06-26 Edmond J. Lavoie Solubilized topoisomerase poison agents
ATE405568T1 (de) * 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
DE60225943T2 (de) * 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase-giftmittel
AU2002363658B2 (en) * 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) * 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
US6989387B2 (en) * 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
AU2003290818A1 (en) * 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
FR2856687B1 (fr) * 2003-06-25 2005-09-16 Servier Lab Nouveaux derives de benzo[a]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
RU2257915C2 (ru) * 2003-10-17 2005-08-10 Государственное учреждение Московский областной научно-исследовательский институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения обострений рассеянного склероза
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2007002867A1 (en) 2005-06-28 2007-01-04 Cv Therapeutics, Inc. Abca1 elevating compounds
US20070110813A1 (en) * 2005-11-02 2007-05-17 Aeris Therapeutics, Inc. Polycation-polyanion complexes, compositions and methods of use thereof
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
MX2008014828A (es) * 2006-05-22 2009-02-06 Combinatorx Inc Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
EP2125825A1 (en) * 2006-12-27 2009-12-02 Cv Therapeutics, Inc. Abca1 elevating compounds
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
CA2709561A1 (en) * 2007-12-17 2009-06-25 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
US7998952B2 (en) 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ［ｉ］フェナントリジン誘導体
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
JP5814933B2 (ja) * 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
WO2015077535A2 (en) 2013-11-22 2015-05-28 Genzyme Corporation Novel methods for treating neurodegenerative diseases
EP3442979A4 (en) 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
AR127618A1 (es) 2021-11-29 2024-02-14 Bayer Ag Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
US4918077A (en) * 1989-01-25 1990-04-17 E. I. Du Pont De Nemours & Co., Inc. 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents
JP2515415B2 (ja) * 1990-02-28 1996-07-10 株式会社東芝 半導体素子の外部リ―ドの成型方法
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5225418A (en) * 1991-12-17 1993-07-06 Du Pont Merck Pharmaceutical Company 5H-(1,2)benzisothiazolo[2,3-a]quinoline-5-ones and analogs as antiinflammatory agents
US5179100A (en) * 1992-03-09 1993-01-12 Hoechst-Roussel Pharmaceuticals Inc. 4,5-dihydropyrazolo[3,4-a]acridines
EP0601191B1 (en) * 1992-04-24 1998-07-22 Kyowa Hakko Kogyo Kabushiki Kaisha Novel tetracyclic compound
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents

Also Published As

Publication number Publication date
NO960811D0 (no) 1996-02-28
PL313981A1 (en) 1996-08-05
NZ273156A (en) 1997-06-24
HUT74585A (en) 1997-01-28
HU9600501D0 (en) 1996-04-29
CZ51696A3 (en) 1996-06-12
CA2170349A1 (en) 1995-03-09
US6110910A (en) 2000-08-29
AU690140B2 (en) 1998-04-23
WO1995006640A1 (en) 1995-03-09
US5874441A (en) 1999-02-23
TW342390B (en) 1998-10-11
IL110821A0 (en) 1994-11-11
FI960933A7 (fi) 1996-02-28
EP0716652A1 (en) 1996-06-19
RU2133740C1 (ru) 1999-07-27
IL110821A (en) 1997-04-15
ZA946658B (en) 1996-02-29
AU7635894A (en) 1995-03-22
HRP940484A2 (en) 1997-02-28
US5639759A (en) 1997-06-17
FI960933A0 (fi) 1996-02-28
US5428040A (en) 1995-06-27
KR960704851A (ko) 1996-10-09
SK27096A3 (en) 1996-12-04
JPH09501442A (ja) 1997-02-10

Similar Documents

Publication Publication Date Title
CN104136436B (zh) 抗纤维化的化合物及其用途
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
JOP20230186A1 (ar) أجسام مضادة لـ cd30l واستخداماتها
US20240239828A1 (en) Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteins
DE69718915D1 (de) Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose
HU229864B1 (en) Use of amide compounds for the preparation of medicaments
MA56226B1 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
DE69231252D1 (de) Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten
Tanner et al. Targeting KCa1. 1 channels with a scorpion venom peptide for the therapy of rat models of rheumatoid arthritis
EA200100872A1 (ru) Композиция валдекоксиба
NO177785C (no) Analogifremgangsmåter for fremstilling av terapeutisk aktive alkoksy-4(1H)-pyridonderivater
ES8706668A1 (es) Un procedimiento para la preparacion de derivados de piperidina.
MY106038A (en) 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents.
DK0529568T3 (da) Nye oralt aktive elastaseinhibitorer
DK472184D0 (da) 2-amino-5-hydroxy-4-methylpyrimidin-derivater og farmeceutiske praeparater indeholdende disse
CN108938642A (zh) 免疫相关和炎性疾病的治疗
El-Sayed et al. In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis
WO2020113146A1 (en) Composition and method for treating dementia
DK0434057T3 (da) Indocarbazol-derivater, fremgangsmåder til deres fremstilling og deres anvendelse
CA2377254A1 (en) Non-malignant disease treatment with ras antagonists
DE69717969D1 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
IT8720438A0 (it) Esteri di 1,4:3,6-dianidrosorbitolo-2-mononitrato e 5-mononitrato, loro procedimento di preparazione e loro composizioni farmaceutiche.
Perosa et al. The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3)
DK149890C (da) Analogifremgangsmaade til fremstilling af n-(4-phenyl-2-thiazolyl)-oxamidsyre-2-ethoxyethylester
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter